ФАКТОРЫ ПРОГНОЗА ВЫЖИВАЕМОСТИ У БОЛЬНЫХ НЕМЫШЕЧНО-ИНВАЗИВНЫМ РАКОМ МОЧЕВОГО ПУЗЫРЯ
Аннотация
Для большинства случаев впервые выявляемого немышечно-инвазивного рака мочевого пузыря (НМИ РМП) характерны склонность к частому рецидивированию, нередко прогрессия к инвазивному раку, а также существенное различие отдаленных результатов лечения пациентов из одной классификационной подгруппы. В литературе широко обсуждается роль многочисленных клинических, гистологических и биологических факторов прогноза, однако результаты исследований в данной области противоречивы или невоспроизводимы. Проблемы прогнозирования течения НМИ РМП остаются неразрешенными.
Ключевые слова
Об авторах
Б. Я. Алексеев
ФГУ МНИОИ им. П.А. Герцена;
Россия
Отделение онкоурологии
Россия
Отделение онкоурологии
Ю. Ю. Андреева
ФГУ МНИОИ им. П.А. Герцена;
Россия
Отделение патологической анатомии
Россия
Отделение патологической анатомии
И. В. Новикова
ГБУЗ ГКБ № 57, Москва
Россия
Отделение онкоурологии
Россия
Отделение онкоурологии
Список литературы
1. Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2012.
2. Kirkali Z., ChanT., Manoharan M. et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(l6A):4 –34.
3. European Association of Urology, Guidelines 2010.
4. Heney N.M., Ahmed F., Flanagan M.J. et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083 –1086.
5. Babjuk M., Oosterlinck W., Sylvester R. et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladdeк,the 2011 Update. Eur Urol 2011; 59:997–1008.
6. Soloway M.S. It is time to abandon the ‘‘superficial’’ in bladder cancer. Eur Urol 2007;52:1564–5.
7. Van Rhijn B.W., Burger M., Lotan Y. et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009;56(3):430–42.
8. Sylvestr R.J., van der Meijden A., Oosterlinck W. et al. Predicting recurrence and progression in individual patients with stage Ta-T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49(3): 466–77.
9. Sanyal S., de Verdier P.J., Steineck G. еt al. Polimorphisms in XPD, XPS and the risk of death in patients with urinary bladder neoplasms. Acta Oncol 2007;46:31–41.
10. Van den Bosch S., Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 2011;60(3):493–500.
11. Матвеев Б.П., Матвеев В.Б., Давыдов М.И. и др. Клиническая онкоурология. Под ред. Б.П. Матвеева. М.: АБВ-пресс, 2011; с. 309–314.
12. Lopez-Beltran A., Luque R.J., Alvarez-Kindelan J. et al. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol 2004;122(3):444–52.
13. Mori Y., Arima M., Sbimada K. et al. Treatment of 300 patients with bladder сancer. Hinyokika Kiyo 1991;37(10):1235–41.
14. Jancke G., Rosell J., Jahnson S. Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder. Scand J Urol Nephrol 2011;45(6):388–92.
15. Jimenez Cruz J.F., Llopis Mingues B., Vera-Donoso C. Primary superficial bladder cancer. Prognostic factors for reccurence. Arh Esp Urology 1990;43(2):139-47.
16. Vukomanovic I., Colovic V., Soldatovic I., Hadzi-Djokic J. Prognostic significance of tumor location in high-grade non-muscle-invasive bladder cancer. Med Oncol 2011;29(3):1916–20.
17. Divrik R.T., Sahin A., Altok M. et al. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer. J Urol 2007;178(3 Pt 1):802–6.
18. Stimson C.J., Cookson M.S., Barocas D.A. et al. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol 2010;183(5):1732–7.
19. Palou J., Sylvester R.J., Rodriguez Faba O. et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol 2012;62:118–25.
20. Touloupidis S., Fatles G., Kalaitzis C. et al. The significance of p53 and bcl-2 overexpression and other prognostic factors in transitional cell carcinoma of the bladder. Int Urol Nephrol 2006;38(2):231–6.
21. Fajkovic H., Halpern J.A., Cha E.K. et al. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 2011;29(4):457–63.
22. Mallin K., David K.A., Carroll P.R. et al. Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). J Urol 2011;185(5):1631–6.
23. Griebling T.L. Impact of patient age on outcome following bladder-preserving treatment for non-muscle-invasive bladder cancer. J Urol 2011;185(2):466–7.
24. Ha M.S., Chang I.H. Significance of age and comorbidity as prognostic indicators for patients with bladder cancer. Asian J Androl 2010;12(5):766–74.
25. Megwalu I.I., Vlahiotis A., Radwan M. et al. Prognostic impact of comorbidity in patients with bladder cancer. Eur Urol 2008;53(3):581–9.
26. Leliveld A.M., Bastiaannet E., Doornweerd B.H. et al. High risk bladder cancer: current management and survival. Int Braz J Urol 2011;37(2):203–10.
27. Hwang E.C., Kim Y.J., Hwang I.S. et al. Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study. Int J Urol 2011;18(11):769–76.
28. Lammers R.J., Witjes W.P., Hendricksen K. et al. Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. Eur Urol 2011;60(4):713–20.
29. Завалишина Л.Э., Андреева Ю.Ю., Маныкин А.А., Франк Г.А. Выявление вируса папилломы человека при опухолях эпителиальной природы. Пособие для врачей. М.: МНИОИ им. П.А. Герцена, 2004.
30. Андреева Ю.Ю., Завалишина Л.Э., Морозов А.А. и др. Выявление ДНК вируса папилломы человека в поверхостной уротелиальной карциноме мочевого пузыря. Онкоурология 2008;(1):34-5.
31. Lopes-Beltran A., Escudero A.L., Vicioso L. et al. Human papillomavirus DNA as a factor determining the survival of bladder cancer patients. Br J Cancer 1996;73:124–7.
32. De Gaetani C., Ferrari G., Righi E. et al. Detection of human papillomavirus DNA in urinary bladder carcinoma by in situ hybridization. J Clin Pathol 1999;52:103–6.
33. Bassi P., Ferrante G.D., Piazza N. et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of homogeneous patient cohort. J Urol 1999;161(5):1494–7.
34. Van Rhijn B.W., van der Kwast T.H., Alkhateeb S.S. et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012;61(2): 378–84.
35. Kruger S., Mahnken A., Kausch I. et al. (2005) P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur Urol 47(4):463 –7.
36. Андреева Ю.Ю. Морфологические и молекулярно-биологические факторы прогноза рака мочевого пузыря. Дис. … докт. мед. наук. М., 2009.
37. Kurt K. et al. The natural history and the prognosis of tread superficial bladder cancer. EORTS GU Group// Prog Clin Biol Res 1992;378:1.
38. Segal R., Yafi F.A., Brimo F. et al. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int 2012;109(7):1026–30.
39. Аничков Я.М., Толыбеков А.С. Уротелий: норма, воспаление, опухоль. Алма-Ата, 1987; с. 5090.
40. Lipponen P.K., Eskelinen M.J., Jauhianinen K. et al. Clinical prognostic factors in transitional cell cancer of the bladder. Urol Int 1993;50(4):192–7.
41. Bertz S., Otto W., Denzinger S. et al. Combination of CK20 and Ki-67 Immunostaining Analysis Predicts Recurrence, Progression, and Cancer-Specific Survival in pT1 Urothelial Bladder Cancer. Eur Urol 2012 May.
42. Korneyev I.A. Prognostic factors in urinary bladder cancer patients // Eur Urol Today 1997;7(2):13.
43. Van der Poel Н.G., van Caubergh R.D., Boon M.E. et al. Kariometry in recurrent superficial transitorial cell tumors of the bladder. Urol Res 1992;20(5):375–81.
44. Toyota K., Nagamori S., Kashiwagi A. et al. Flow cytometric analysis of the DNA content in the urinary bladder cancers treated by radical cystectomy and pre_operative irradiation. Nippon Hiyokika Gakkai Zasshi 1992;83(12):2050–7.
45. Wang X.Z., Ma Y.J., Zheng J.F., Qin H.Y. DNA malignancy grading of bladdertumor and its clinical significance. Chin Med J Engl 1992;105 (10):856–9.
46. Mhawech-Fauceglia P., Cheney R.T., Fischer G. et al. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol 2006;32(2):231–7.
47. Karamitopoulou E., Rentsch C.A., Markwalder R. et al. Prognostic significance of apoptotic cell death in bladder cancer: a tissue microarray study on 179 urothelial carcinomas from cystectomy specimens. Pathology 2010;42(1):37–42.
48. Wolf H.K., Stöber C., Hohenfellner R., Leissner J. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas. Tumour Biol 2001;22(5):328–36.
49. Erill N., Colomer A., Verdú M., Román R. et al. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression. Diagn Mol Pathol 2004;13(4):217–23.
50. Rammeh-Rommani S., Zermani R., Sfaxi M. et al. Prognostic value of the immunohistochemical expression of: Ki-67, p53, PCNA and Bc-l2 in the superficial tumors of the bladder. Tunis Med 2007;85(6):509–12.
51. Ong F., Moonen L.M., Gallee M.P. et al. Prognostic factor in transitional cell cancer of the bladder: an emerging role for bcl-2 and p53. Radioter Oncol 2001;61:169–75.
52. Bustos A., Nascimento C.M., Fernandez F. et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005;6(9):678–86.
53. Goebell P.J., Groshen S.G., Schmitz-Dräger B.J. International Study-Initiative on Bladder Cancer (ISBC). p53 immunohistochemistry in bladder cancer-a new approach to an old question. Urol Oncol 2010;28(4):377–88.
54. Cai T., Piazzini M., Nesi G. et al. E-cadherin mRNA expression analysis in evaluating the natural history of urothelial bladder cell carcinoma: results from a long-term follow-up study. Oncol Rep 2007;17(4):925–30.
55. Muramaki M., Miyake H., Terakawa T. et al. Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. Urol Oncol 2010;5.
56. Baumgart E., Cohen M.S., Silva Neto B. et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res 2007;13(6):1685–94.
57. Szarvas T., Hoffmann F., Becker M. et al. Plasma E-cadherin levels in urinary bladdercancer: does it improve risk stratification? Urologe A 2011;50(1):64–70.
58. Levine A.I., Schmidek H.H. Molecular genetics of nervous system tumors. New-York, Wiley-Liss., 1993.
59. Brunner A., Mayerl C., Tzankov A. et al. Prognostic significance of tenascin C expression in superficial and invasive bladder cancer. J Clin Pathol 2004;57(9):927–31.
60. Richter P., Tost M., Franz M. et al. B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder? J Cancer Res Clin Oncol 2009;135(10):1351–8.
Для цитирования:
Алексеев Б.Я., Андреева Ю.Ю., Новикова И.В. ФАКТОРЫ ПРОГНОЗА ВЫЖИВАЕМОСТИ У БОЛЬНЫХ НЕМЫШЕЧНО-ИНВАЗИВНЫМ РАКОМ МОЧЕВОГО ПУЗЫРЯ. Онкоурология. 2013;9(1):34-42. https://doi.org/10.17650/1726-9776-2013-9-1-34-42
For citation:
Alekseev B.Y., Andreeva Y.Y., Novikova I.V. PROGNOSTIC FACTORS OF SURVIVAL IN NON-MUSCLE-INVASIVE BLADDER CANCER. Cancer Urology. 2013;9(1):34-42. (In Russ.) https://doi.org/10.17650/1726-9776-2013-9-1-34-42
Просмотров: 484
Послать статью по эл. почте 